Online citations, reference lists, and bibliographies.
← Back to Search

Pemetrexed Plus Cisplatin Or Pemetrexed Plus Carboplatin For Chemonaïve Patients With Malignant Pleural Mesothelioma: Results Of The International Expanded Access Program

A. Santoro, M. O'Brien, R. Stahel, K. Nackaerts, P. Baas, M. Karthaus, W. Eberhardt, L. Paz-Ares, S. Sundstrøm, Y. Liu, V. Ripoche, J. Blatter, C. Visseren-Grul, C. Manegold
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction: Previously published results from a randomized phase III study of pemetrexed plus cisplatin in patients with malignant pleural mesothelioma (MPM) demonstrated a significant survival benefit and higher response rate compared with cisplatin. Although pemetrexed was under review by regulatory agencies, an International Expanded Access Program (EAP) provided more than 3000 mesothelioma patients with access to single-agent pemetrexed or pemetrexed in combination with cisplatin or carboplatin in 13 countries. This manuscript reports the safety and efficacy data from the nonrandomized open-label study in chemonaïve patients receiving pemetrexed plus platinum under the EAP. Methods: Patients with histologically confirmed MPM, not amenable to curative surgery, received pemetrexed 500 mg/m2 in combination with either cisplatin 75 mg/m2 or carboplatin AUC 5, once every 21 days with standard premedication. Efficacy data were recorded at the end of study participation. Results: A total of 1704 chemonaïve patients received pemetrexed plus cisplatin (n = 843) or pemetrexed plus carboplatin (n = 861) and were evaluated for safety. The efficacy evaluable population consisted of 745 patients in the pemetrexed plus cisplatin group and 752 patients in the pemetrexed plus carboplatin group for whom physician-reported tumor response was available. The pemetrexed plus cisplatin group demonstrated a response rate of 26.3% compared with 21.7% for the pemetrexed plus carboplatin group, with similar 1-year survival rates (63.1% versus 64.0%) and median time to progressive disease (7 months versus 6.9 months). The most common grade 3/4 hematologic toxicity was neutropenia in 23.9% of the pemetrexed plus cisplatin group and 36.1% of the pemetrexed plus carboplatin group. Conclusion: This large EAP confirmed the activity of pemetrexed plus cisplatin and pemetrexed plus carboplatin in chemonaïve patients with MPM, demonstrating clinically similar time to progressive disease and 1-year survival rates.
This paper references
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1097/01.JTO.0000283218.40896.16
C5-03: Open-label study of pemetrexed alone or in combination with a platinum for previously treated patients (pts) with malignant pleural mesothelioma (MPM): Outcomes from the International Expanded Access Program (EAP)
U. Gatzemeier (2007)
Phase II study of pem etrexed and carboplatin in malignant pleural mesothelioma
GL Ceresoli (2006)
10.1093/jnci/92.3.205
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
Phase II study of combination chemotherapy with Cytoxan (C), Adriamycin (A), and cisplatin (P) for unresectable or metastatic malignant pleural mesothelioma (MPM)
DM Shin (1993)
10.1016/0169-5002(94)90550-9
Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma.
N. Tsavaris (1994)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
Phase II study of pemetrexed and carboplatin in malignant pleural mesothelioma
GL Ceresoli (2006)
10.1016/J.LUNGCAN.2006.09.023
Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
C. Obasaju (2007)
10.1093/ANNONC/MDM027
Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
C. Manegold (2007)
International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma
(1995)
10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
Reporting results of cancer treatment
A. Miller (1981)
Common Toxicity Criteria, Version 2.0. DCTD, NCI, NIH, DHHS
(1998)
10.1200/JCO.1993.11.8.1559
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
A. Chahinian (1993)
Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY 231514) in combination with cisplatin
R Thodtmann (1999)
10.1200/JCO.2002.10.073
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
A. Hughes (2002)
10.1097/01.JTO.0000283216.33273.F0
C5-01: Open-label study of pemetrexed alone or in combination with a platinum in chemonaïve patients (pts) with malignant pleural mesothelioma (MPM): Results from the International Expanded Access Program (EAP)
C. Manegold (2007)
10.1200/JCO.1996.14.3.1007
Chemotherapy in malignant pleural mesothelioma. A review.
S. T. Ong (1996)
Adriamycin (A), and cisplatin (P) for unresectable or metastatic malignant pleural mesothelioma (MPM)
D M Shin
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
P. Therasse (2000)
Single arm, open label study of pemetrexed plus cisplatin in chemotherapy naı̈ve patients with malignant pleural mesothelioma: outcomes of an expanded access program. Lung Cancer 2007;55:187–194
CK Obasaju (2007)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.1378/CHEST.116.2.504
Advances in the treatment of malignant pleural mesothelioma.
D. Sterman (1999)
10.1200/JCO.1999.17.10.3009
Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin.
R. Thödtmann (1999)
Coordinating author for the ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment, and follow-up
C. Manegold (2007)
10.1159/000180580
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft Dw (1976)
10.1002/1097-0142(19910615)67:12<2984::AID-CNCR2820671208>3.0.CO;2-Q
Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An italian lung cancer task force (FONICAP) phase II study
A. Ardizzoni (1991)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1007/BF00944177
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
S. Green (2004)
10.1093/OXFORDJOURNALS.ANNONC.A059253
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.
A. Planting (1995)
10.1378/CHEST.126.4.1318
Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies.
M. Pistolesi (2004)
10.1634/THEONCOLOGIST.9-5-482
FDA drug approval summaries: pemetrexed (Alimta).
M. Hazarika (2004)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1159/000180580
Prediction of creatinine clearance from serum creatinine.
D. Cockcroft (1975)
Task Force ( FONICAP ) phase II study
AP Chahinian (1991)



This paper is referenced by
10.1097/CAD.0b013e32834d7a1c
A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma
V. Kovač (2012)
10.1097/MD.0000000000003351
Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma
Xu-quan Jing (2016)
10.1016/j.cllc.2019.08.008
Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience.
D. Franceschini (2019)
10.1200/JCO.2009.25.9275
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
L. Righi (2010)
10.1007/s10405-009-0350-0
Therapie des malignen Pleuramesothelioms
Hanno Huwer (2009)
10.1016/j.cllc.2014.06.009
Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
Tomasz Powrózek (2014)
10.1016/j.critrevonc.2019.102815
Emerging therapies in malignant pleural mesothelioma.
Marika Cinausero (2019)
10.1097/JTO.0b013e3181f41b1c
Compassionate Use Programs or Phase IV Trials of Innovative Molecular Targeted Drugs in Lung Cancer: Deal or No Deal?
Wilfried Ernst Erich Eberhardt (2010)
The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
Christel C. L. M. Boons (2013)
10.5301/tj.5000364
Sarcomatoid Mesothelioma: Future Advances in Diagnosis, Biomolecular Assessment, and Therapeutic Options in a Poor-Outcome Disease
Domenico Galetta (2016)
10.1016/J.CERAMINT.2013.02.084
Effect of amine and carboxyl functionalization of sub-micrometric MCM-41 spheres on controlled release of cisplatin
C. O. Arean (2013)
10.1007/978-3-662-48727-3_39
Pleuramesotheliom beim alten und geriatrischen Patienten
Martin Steins (2018)
10.4172/2472-1247.1000134
The Role of Immunotherapy in Malignant Mesothelioma
Kastelik Ja (2018)
10.6004/JNCCN.2016.0087
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.
D. Ettinger (2016)
10.1016/j.lungcan.2010.12.021
Pemetrexed re-challenge in pleural malignant mesothelioma: an option for a subset of patients initially treated with pemetrexed-platinum doublets in the first-line setting?
Gérard Zalcman (2011)
10.1016/S1877-1203(16)30135-5
Traitement du mésothéliome pleural malin en 2016
Arnaud Scherpereel (2016)
10.1016/j.ctrv.2012.11.004
Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations.
C. Pinto (2013)
RECENT TRENDS IN THE MANAGEMENT OF MESOTHELIOMA - A RARE FORM OF CANCER: A REVIEW
Roop Kishor (2010)
10.1007/978-2-287-99041-0_20
Mésothéliome pleural malin
E. Bergot (2009)
10.4155/CLI.11.72
Treatment of malignant pleural mesothelioma: current status and future directions
Paolo Andrea Zucali (2011)
10.1007/s12032-012-0276-y
Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients
Emin Tamer Elkıran (2012)
10.7314/APJCP.2014.15.10.4117
ERCC1 as a biological marker guiding management in malignant pleural mesothelioma.
Y. Cihan (2014)
10.3978/j.issn.2225-319X.2012.10.05
Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future.
A. Nowak (2012)
10.1155/2013/572609
A Potential Therapeutic Strategy for Malignant Mesothelioma with Gene Medicine
Y. Tada (2013)
10.2146/ajhp110281
Malignant pleural mesothelioma.
Sheree E Chen (2012)
10.1016/j.ejbas.2018.05.007
Malignant pleural mesothelioma: Presentation of a case report
Munir Ahmad (2018)
10.1080/17476348.2019.1678386
Approved and emerging treatments of malignant pleural mesothelioma in elderly patients
Giovanni Luca Ceresoli (2019)
10.3389/fonc.2017.00179
Oncolytic Viral Therapy for Mesothelioma
D. Pease (2017)
10.4103/0970-2113.48900
Malignant pleural mesothelioma
S. Rao (2009)
10.1016/j.jtho.2018.04.023
New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi‐Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center
F. Sallé (2018)
10.1080/14737140.2016.1191951
Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges
G. Ceresoli (2016)
10.1136/thoraxjnl-2018-212967
Palliative care in mesothelioma: Are current services RESPECT-able enough?
N. Kumar (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar